OasisLMS

Upon completion of this educational activity, participants will be able to (or better able to):

• To review lipid metabolism and understand the metabolic abnormalities leading to dyslipidemia and its complications.
• To recognize secondary causes of dyslipidemia.
• To discuss the mechanism of action and indications of lipid-modifying therapies
• To demonstrate confidence in the use of evidence-based combination therapy and compare the efficacy of the various treatment approaches.
• To effectively address statin intolerance in patients at increased cardiovascular risk, recognizing individual patient needs and preferences.
• To identify patients with genetic dyslipidemia and understand the underlying metabolic pathology.

Om Ganda, MD
Harvard Medical School

Zahid Ahmad, MD
UT Southwestern

Marcelo, Correia MD, MScPhD, DABOM 
University of Iowa

STATEMENT OF INDEPENDENCE 

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force. 

DISCLOSURE POLICY 

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. 

The following faculty reported the following relevant financial relationships: 

Zahid Ahmad, MD serves on the Board of Directors for the National Lipid Association and serves as a Chair for the Amyrt MEASURE Adjudication Committee.

Marcelo Correia, MD, MScPhD, DABOM  is a Member of the The Obesity Society and serves as a  Principal Investigator for  Novartis, Eli Lilly and  Novo Nordisk. He is also a consultant for Novo Nordisk and is a Research Grant Recipient from the Stead Family.

The following faculty reported no relevant financial relationship: Om Ganda, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships. 

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.